Reversing metabolic reprogramming by CPT1 inhibition with etomoxir promotes cardiomyocyte proliferation and heart regeneration via DUSP1 ADP-ribosylation-mediated p38 MAPK phosphorylation.
10.1016/j.apsb.2024.11.001
- Author:
Luxun TANG
1
;
Yu SHI
1
;
Qiao LIAO
1
;
Feng WANG
1
;
Hao WU
1
;
Hongmei REN
1
;
Xuemei WANG
1
;
Wenbin FU
1
;
Jialing SHOU
1
;
Wei Eric WANG
1
;
Pedro A JOSE
2
;
Yongjian YANG
3
;
Chunyu ZENG
1
Author Information
1. Department of Cardiology, Daping Hospital, the Third Military Medical University (Army Medical University), Chongqing 400042, China.
2. Division of Renal Diseases and Hypertension, the George Washington University School of Medicine and Health Sciences, Washington, DC 20541, USA.
3. Department of Cardiovascular Medicine, the General Hospital of Western Theater Command, Chengdu 610083, China.
- Publication Type:Journal Article
- Keywords:
ADP-ribosylation;
Cardiomyocyte proliferation;
Carnitine palmitoyltransferase 1;
Etomoxir;
Fatty acid oxidation;
Glycolysis;
Metabolic reprogramming;
p38 MAPK
- From:
Acta Pharmaceutica Sinica B
2025;15(1):256-277
- CountryChina
- Language:English
-
Abstract:
The neonatal mammalian heart has a remarkable regenerative capacity, while the adult heart has difficulty to regenerate. A metabolic reprogramming from glycolysis to fatty acid oxidation occurs along with the loss of cardiomyocyte proliferative capacity shortly after birth. In this study, we sought to determine if and how metabolic reprogramming regulates cardiomyocyte proliferation. Reversing metabolic reprogramming by carnitine palmitoyltransferase 1 (CPT1) inhibition, using cardiac-specific Cpt1a and Cpt1b knockout mice promoted cardiomyocyte proliferation and improved cardiac function post-myocardial infarction. The inhibition of CPT1 is of pharmacological significance because those protective effects were replicated by etomoxir, a CPT1 inhibitor. CPT1 inhibition, by decreasing poly(ADP-ribose) polymerase 1 expression, reduced ADP-ribosylation of dual-specificity phosphatase 1 in cardiomyocytes, leading to decreased p38 MAPK phosphorylation, and stimulation of cardiomyocyte proliferation. Our present study indicates that reversing metabolic reprogramming is an effective strategy to stimulate adult cardiomyocyte proliferation. CPT1 is a potential therapeutic target for promoting heart regeneration and myocardial infarction treatment.
